Skip to main
CTSO
CTSO logo

CytoSorbents (CTSO) Stock Forecast & Price Target

CytoSorbents (CTSO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CytoSorbents Corp is focused on advancing its product portfolio, particularly DrugSorb-ATR, while seeking to enhance growth in its core product, CytoSorb, and improve margins as it approaches near-breakeven operations by the end of 2025. The company's strategy emphasizes cost management and expanding market adoption, which are critical for driving operational efficiency and financial stability. Additionally, the potential for new regulatory filings in Canada, contingent on improved FDA visibility, presents a promising catalyst for future growth and market expansion.

Bears say

CytoSorbents Corp faces significant challenges due to its dependency on the German market for revenue generation, which may hinder growth potential in a highly competitive global landscape. Additionally, the company has encountered obstacles in securing consistent funding from grant agencies in the United States, impacting its financial stability and operational capacity. Furthermore, while CytoSorbents' product portfolio includes several specialized medical technologies, the slower than anticipated adoption rates and reliance on direct sales and partnerships raise concerns about sustainable revenue growth and overall profitability.

CytoSorbents (CTSO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CytoSorbents (CTSO) Forecast

Analysts have given CytoSorbents (CTSO) a Buy based on their latest research and market trends.

According to 3 analysts, CytoSorbents (CTSO) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CytoSorbents (CTSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.